MdxHealth (TM) : MDxHealth Announces Results from the ConfirmMDx(TM) for Prostate Cancer Test Studies Presented at the 2013 ASCO

   MdxHealth (TM) : MDxHealth Announces Results from the ConfirmMDx(TM) for
Prostate Cancer Test Studies Presented at the 2013 ASCO Genitourinary Cancers
                                  Symposium

IRVINE, CA,  and LIEGE,  BELGIUM -  February  18, 2013  - MDxHealth  SA  (NYSE 
Euronext: MDXH),  a leading  molecular diagnostic  company that  develops  and 
commercializes epigenetic  tests to  support the  diagnosis and  treatment  of 
cancer  patients,  today  announced  the   results  of  two  studies  of   the 
ConfirmMDx(TM) for Prostate  Cancer test presented  at the ASCO  Genitourinary 
Cancers Symposium 2013, February 14-16, Orlando, Florida, USA.

"These additional clinical studies add to our extensive body of  peer-reviewed 
evidence, clearly demonstrating the ability of ConfirmMDx for Prostate  Cancer 
test to  provide  valuable diagnostic  information  to support  urologists  in 
better patient management," said Jesse Savala, M.D., clinical pathologist  and 
Medical Director  at  MDxHealth.  "With  the advances  being  made  in  human 
epigenetics, we believe that DNA  methylation-based tests hold the promise  to 
improve the diagnosis and subsequent treatment of cancer patients."

Studies clearly show that the ConfirmMDx(TM) for Prostate Cancer test provides
very important personalized information that cannot be achieved with
traditional procedures:

  oIn the Epigenetic Field Effect study in Histologically Benign Prostate
    Biopsy Cores it was shown that GSTP1, APC and/or RASSF1 gene promoter
    methylation is more prevalent in histologically benign cores from prostate
    cancer (PCa) patients diagnosed with Gleason Score (GS) 7 PCa, as compared
    with low volume GS 6. This study confirms previous findings in a larger
    cohort of subjects that these "field effect" biomarkers can be useful for
    detecting cancer adjacent to histologically negative biopsies and may be
    indicative of occult aggressive PCa.
    
  oThe multi-gene ConfirmMDx(TM) for Prostate Cancer test demonstrated that
    epigenetic profiling is a significant predictor for PCa risk, especially
    to identify those men who should (not) undergo a repeat biopsy following a
    negative initial biopsy. An integrated risk management approach that
    combines this epigenetic assay with other risk factors, most notably
    histopathologic features of the cancer-negative initial biopsy, resulted
    in an improved prediction for the presence of PCa with sensitivity and
    negative predictive values of respectively 74% and 91%.

About ConfirmMDx for Prostate Cancer
Over 650,000 American men receive a negative prostate biopsy result each year;
though approximately25% of these men may still harbor occult prostate  cancer. 
This  well-documented  risk  of  undetected  cancer,  often  with   clinically 
significant disease leads to a high rate  of repeat biopsies with over 40%  of 
men receiving at least one repeat biopsy,  and many receiving a 3^rd and  4^th 
biopsy. Today's  gold  standard diagnostic  approach  is the  prostate  biopsy 
procedure, collecting 10-12 needle core biopsy samples, however this  sampling 
represents less than 1% of a man's prostate. ConfirmMDx for Prostate Cancer is
an epigenetic  assay  to  help  urologists distinguish  patients  who  have  a 
true-negative biopsy from those at risk for occult cancer. The test is able to
detect an epigenetic field effect or "halo" resulting from oncogenic processes
at the DNA  level in  cells adjacent to  cancer foci.  This molecular  "halo" 
around a cancer lesion can be present despite having a normal appearance under
the microscope. The test  helps urologists rule  out prostate cancer-free  men 
from undergoing  unnecessary repeat  biopsies  and, helps  rule in  high  risk 
patients who may require repeat biopsies and potential treatment.

About MDxHealth
MDxHealth is a molecular diagnostics company that develops and  commercializes 
advanced epigenetic tests for cancer assessment and the personalized treatment
of patients. The  company's first commercial  product, the ConfirmMDx(TM)  for 
Prostate Cancer test, has been shown  to help distinguish patients who have  a 
true-negative biopsy from those who may have occult cancer. MDxHealth helps to
address a large and growing unmet medical need for better cancer diagnosis and
treatment information. The  company has  a proprietary platform  and a  strong 
epigenetic product pipeline focused on  the development of products for  brain 
and lung cancers. The company is  based in Irvine, California with a  European 
headquarters in Liege, Belgium. For  more information visit MDxHealth  website 
at www.mdxhealth.com.

Contacts 
Dr Jan Groen, CEO
MDxHealth
US: +1 949 812 6979
BE: +32 4 364 20 70
info@mdxhealth.com

Mike Sinclair
Halsin Partners
UK: +44 20 7318 2955
Cell: +44 7968 022075
msinclair@halsin.com

Seth Lewis
The Trout Group
US: +1 646 378 2952
slewis@troutgroup.com




This press  release contains  forward-looking  statements and  estimates  with 
respect to the anticipated future performance  of MDxHealth and the market  in 
which it operates. Such statements and estimates are based on assumptions  and 
assessments of known and unknown risks, uncertainties and other factors, which
were deemed reasonable  but may  not prove to  be correct.  Actual events  are 
difficult to predict, may  depend upon factors that  are beyond the  company's 
control, and  may turn  out to  be materially  different. MDxHealth  expressly 
disclaims any obligation to update any such forward-looking statements in this
release to reflect any change in  its expectations with regard thereto or  any 
change in events, conditions or circumstances  on which any such statement  is 
based unless  required by  law  or regulation.  This  press release  does  not 
constitute an offer or  invitation for the sale  or purchase of securities  or 
assets of MDxHealth  in any jurisdiction.  No securities of  MDxHealth may  be 
offered or sold within the United  States without registration under the  U.S. 
Securities Act  of  1933, as  amended,  or  in compliance  with  an  exemption 
therefrom, and in accordance with any applicable U.S. securities laws.

NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx and PredictMDx are trademarks
or registered trademarks of MDxHealth SA. All other trademarks and service
marks are the property of their respective owners.

ASCO SYMPOSIUM ENG

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: MdxHealth (TM) via Thomson Reuters ONE
HUG#1678617
 
Press spacebar to pause and continue. Press esc to stop.